| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 177.230 | 169.220 | 176.174 | 182.090 | 175.829 | 213.821 | 206.457 | 249.170 | 397.874 | 436.292 |
| Total Income - EUR | 177.457 | 169.532 | 176.280 | 182.489 | 175.840 | 213.838 | 206.893 | 249.186 | 397.887 | 436.813 |
| Total Expenses - EUR | 167.995 | 160.471 | 169.027 | 176.702 | 172.460 | 194.258 | 188.795 | 235.022 | 380.462 | 420.459 |
| Gross Profit/Loss - EUR | 9.462 | 9.061 | 7.254 | 5.787 | 3.380 | 19.580 | 18.098 | 14.165 | 17.425 | 16.354 |
| Net Profit/Loss - EUR | 7.737 | 7.639 | 5.465 | 3.957 | 1.588 | 16.562 | 15.372 | 12.165 | 15.074 | 13.926 |
| Employees | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 |
Check the financial reports for the company - Elixir Pharm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2.022 | 1.485 | 2.063 | 1.177 | 664 | 409 | 195 | 20.377 | 15.956 | 11.565 |
| Current Assets | 53.392 | 46.914 | 52.631 | 62.427 | 59.920 | 77.502 | 73.916 | 115.429 | 147.863 | 141.464 |
| Inventories | 20.056 | 24.653 | 26.378 | 23.486 | 20.760 | 29.026 | 27.333 | 54.684 | 59.129 | 55.434 |
| Receivables | 17.754 | 10.011 | 23.519 | 30.613 | 22.499 | 27.483 | 24.920 | 43.492 | 57.588 | 48.541 |
| Cash | 15.582 | 12.249 | 2.734 | 8.328 | 16.660 | 20.994 | 21.664 | 17.253 | 31.146 | 37.489 |
| Shareholders Funds | 26.459 | 14.780 | 12.484 | 10.848 | 8.345 | 32.494 | 25.486 | 24.923 | 39.921 | 45.321 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 9.344 | 9.137 | 9.166 | 9.138 | 9.087 |
| Debts | 28.955 | 33.707 | 42.210 | 53.019 | 52.495 | 45.669 | 48.626 | 110.883 | 124.027 | 107.709 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Elixir Pharm S.r.l.